Enveric Biosciences Inc vs Heron Therapeutics Inc — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while Heron Therapeutics Inc trades at $0.49 (market cap $84.50M). The key difference: Heron Therapeutics Inc is far larger — about 15.9× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.
| ENVB | HRTX | |
|---|---|---|
Market Cap | $5.32M | $84.50M |
Sector | Health | Health |
52-Week High | $17.40 | $2.02 |
52-Week Low | $1.28 | $0.39 |
Enterprise Value | $408.82K | $182.40M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Heron Therapeutics (HRTX) trades at $0.49, up 13.93% today, showing volatile momentum amid mixed technical signals. The company maintains strong gross margins of 71.12% but struggles with profitability, posting a net loss of $20.20 million in 2025. Recent Q1 2026 earnings missed expectations with a $0.04 loss per share, though management reaffirmed full-year guidance. Analyst consensus remains overwhelmingly bullish with 94.74% buy ratings, contrasting with a recent Zacks Strong Sell designation.
HRTX presents a high-risk opportunity with significant analyst support but persistent financial challenges. The bullish sentiment stems from potential patent developments and commercial execution, while risks include ongoing losses, competitive pressures, and the discrepancy between analyst optimism and recent negative ratings. The stock's current valuation at 0.49x sales appears reasonable if the company can achieve profitability.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →